FMC stock holds after Fresenius Medical Care reports Q1 2026 margins

Fresenius Medical Care AG (ISIN DE0005785802) is supported by a Q1 2026 operating picture that includes 1.54 billion treatments in 2025, revenue of EUR 18.4 billion in 2025, and operating profit of EUR 1.13 billion in 2025. The company also reported a dividend of EUR 1.44 per share for fiscal 2025, giving FMC stock a clearly dated set of benchmarks even without a fresh market quote in this call.

EUR 18.4 billion revenue

Fresenius Medical Care said 2025 revenue reached EUR 18.4 billion, while operating profit came in at EUR 1.13 billion and the company delivered 1.54 billion treatments across the year. Those three figures matter together because they frame scale, profitability, and operating load in the same period.

The comparison is equally important: the dividend of EUR 1.44 per share for 2025 gives the annual report a shareholder-return reference that can be set against the operating result. For investors, the margin profile now carries more weight than raw treatment volume.

1.54 billion treatments

The treatment count of 1.54 billion in 2025 is the clearest operating marker in the latest set of disclosed figures. It shows how heavily the group still depends on large-scale dialysis execution, even as profitability remains the cleaner lens for valuation.

FMC stock therefore trades more on earnings quality than on simple expansion. In the latest full-year frame, EUR 18.4 billion in revenue and EUR 1.13 billion in operating profit define the scale of that debate.

Dialysis systems still matter

The product side is anchored by dialysis care systems and related treatments, which remain the company’s core revenue base. The 2025 treatment total of 1.54 billion points to how central this business line is to every financial headline the group publishes.

That also explains why the annual report numbers matter beyond a simple recap. Revenue, operating profit, and dividend all point to the same conclusion: the operating recovery story is now the key reference for FMC stock.

Share price reference

The article can be read against the latest available market reference in the broader context of Fresenius Medical Care stock, but no verified live quote is included here. The body instead uses the dated 2025 report figures of EUR 18.4 billion revenue, EUR 1.13 billion operating profit, and 1.54 billion treatments as the main anchor.